1 / 6

Memantine in Vascular Dementia: Subgroup Analyses

Memantine in Vascular Dementia Möbius H.J. and Stöffler A. International Psychogeriatrics 2003, 15 Suppl 1: 207-213. Memantine in Vascular Dementia: Subgroup Analyses. Analyses based on studies in patients with mild to moderate vascular dementia: Orgogozo et al. (2002) (MMM300)

qamar
Download Presentation

Memantine in Vascular Dementia: Subgroup Analyses

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Memantine in Vascular DementiaMöbius H.J. and Stöffler A.International Psychogeriatrics 2003, 15 Suppl 1: 207-213

  2. Memantine in Vascular Dementia: Subgroup Analyses Analyses based on studies in patients with mild to moderate vascular dementia: • Orgogozo et al. (2002) (MMM300) • Wilcock et al. (2002) (MMM500) • ADAS-cog analysis by severity at baseline: • MMSE 20-22 • MMSE 15-19 • MMSE 10-14 • ADAS-cog analysis by neuroradiological findings at baseline: • Macrolesions, “Large Vessel Disease” • No macrolesions, “Small Vessel Disease” Möbius and Stöffler, Int Psychogeriatr 2003

  3. ADAS-cog mean change from baseline ITT, LOCF, N = 214 -2 -1 0 1 2 3 Pooled data Improvement ADAS-cog score difference  Memantine (20 mg/day)  Placebo Worsening 0 12 28 Week Patients with “Large Vessel Disease” Hardly Show Cognitive Decline Möbius and Stöffler, Int Psychogeriatr 2003

  4. ADAS-cog mean change from baseline ITT, LOCF, N = 553 -2 -1 0 1 2 3 Pooled data * Improvement  Memantine (20 mg/day)  Placebo Worsening 0 12 28 Week *p = 0.002 versus placebo Significant Benefit of Memantine in Patients with “Small Vessel Disease” ADAS-cog score difference Möbius and Stöffler, Int Psychogeriatr 2003

  5. Largest Benefit of Memantine in More Severely Demented Patients Mean ADAS-cog change from baseline ITT, LOCF -2 -1 0 1 2 3 4 5 -1.38 -0.80 Improvement 0.32 0.50 0.53 0.99 0.94 0.95 ADAS-cog score difference 1.35  Memantine (20 mg/day)  Placebo 2.43 Worsening 4.12 4.40 20-22 15-19 10-14 20-22 15-19 10-14 MMSE at baseline MMM500 MMM300 Möbius and Stöffler, Int Psychogeriatr 2003

  6. Summary The strongest effect of memantine on cognition was shown • in the moderately demented patient population (MMSE < 15 at baseline) and • in the subgroup of patients with “small vessel disease” (no macrolesions in CT/MRI) Möbius and Stöffler, Int Psychogeriatr 2003

More Related